BioGenes selected as new partner for cNEUPRO

Germany's BioGenes GmbH has been chosen as a new partner of cNEUPRO, a European Union-funded research project aiming to analyze  neurodegenerative diseases and discover novel biomarkers, and so improve  early and differential diagnosis of Alzheimer's dementia.

BioGenes will provide laboratory facilities and key personnel to develop  specific monoclonal antibodies against novel neurochemical dementia  biomarkers in blood and cerebrospinal fluid that have been identified  during the project. These monoclonal antibodies may not only be used for  diagnostics, but also have potential as therapeutic agents since they  may access the CNS space.

Reliable differential clinical diagnosis of very early dementia stages  is crucial for choosing the most effective therapeutic strategy. Recent  research has demonstrated that multiparametric neurochemical dementia  diagnostics in cerebrospinal fluid does improve early and differential  diagnosis of dementias. cNEUPRO will help establish European standard  operation procedures for NDD and launch NDD reference centers in  Portugal and Hungary.